Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its pre-clinical program being executed as part of a commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft Polymer"), an innovative healthcare industry services company.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF)是一家临床阶段生物技术公司,专注于开发药物治疗物质滥用和精神健康障碍。该公司很高兴提供其与Graft Polymer (UK) Plc (LSE: GPL)("Graft Polymer")进行商业合作的一部分正在执行的临床前项目的进展。
The collaboration focuses on developing a new class of therapeutics for the potential treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13 million adults in the U.S. and 20 million collectively in the US and other key international markets.
该合作致力于开发一类新的治疗创伤相关精神健康障碍的药物,例如创伤后应激障碍("PTSD"),该疾病影响着美国1300万成年人和美国以及其他关键国际市场共计2000万人。
Recent progress includes:
最近的进展包括:
- Lead chemical series identified: Two chemical series have been identified as co-leads for further development. These series represent a promising new class of compounds with the potential to improve treatment options for trauma-related mental health disorders such as PTSD. The selection of these co-lead candidates is a pivotal step in the drug development process.
- 确定首要化学系列:已确定两个化学系列为进一步研发的共同领导。这些系列代表了一类具有潜力改善创伤相关精神健康障碍如PTSD的治疗选择的新型化合物。选择这些共同领导候选人是药物研发过程中的关键步骤。
- Synthesis pathways defined: The synthesis pathways for these compounds successfully established. This achievement is crucial, as it enables efficient and scalable production of the drug candidates, which will be essential as the collaboration moves towards more advanced pharmacological testing.
- 定义合成途径:这些化合物的合成途径已经成功建立。这一成就是至关重要的,因为它使得药物候选物的高效可扩展生产成为可能,这对于合作伙伴关系向更先进的药理测试迈进至关重要。
- Charnwood Discovery selected as synthesis partner: Awakn has selected Charnwood Discovery, a respected UK-based provider of drug discovery services, as its synthesis partner. The selection of Charnwood Discovery, known for its technical expertise, ensures that the synthesis process will be conducted to a high standard.
- 选择Charnwood Discovery作为合成合作伙伴:Awakn已选择Charnwood Discovery作为合成合作伙伴,Charnwood Discovery是一家备受尊重的英国药物发现服务提供商。选择Charnwood Discovery确保合成过程达到高标准。
- New provisional patent filed: On 27 August 2024, Awakn filed a provisional patent application with the US Patent and Trademark Office, covering a new class of aminoindane chemical entities and their derivatives. This provisional patent has been incorporated into the scope of the commercial collaboration agreement between the Company and Awakn. This filing strengthens the intellectual property portfolio underpinning the Graft Polymer-Awakn collaboration, further reinforcing the Company's competitive edge in the biopharmaceutical market.
- 新的临时专利申请已提交:2024年8月27日,Awakn向美国专利商标局提交了一项对新型氨基茚化合物及其衍生物的临时专利申请。此临时专利已纳入公司与Awakn之间的商业合作协议范围。此申请加强了支撑Graft Polymer-Awakn合作关系的知识产权组合,进一步增强了该公司在生物制药市场的竞争优势。
Anthony Tennyson, CEO of Awakn Life Sciences, commented: "We are making great strides in our collaboration with Graft Polymer as we move closer to developing a new class of therapeutics to tackle PTSD and other trauma-related conditions. These advancements represent a major step forward in our mission to deliver more effective solutions for those suffering from mental health disorders."
Awakn Life Sciences首席执行官Anthony Tennyson评论道:“在与Graft Polymer的合作中,我们正向着研发一类新的治疗方法来解决创伤后应激障碍(PTSD)和其他与创伤相关的疾病取得重大进展。这些进展代表了我们使命中的重要一步,即为患有精神健康障碍的患者提供更有效的解决方案。”
About Awakn Life Sciences Corp.
关于Awakn Life Sciences Corp。
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting substance use and mental health disorders. Awakn has a near-term focus on AUD , a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
Awakn Life Sciences Corp.是一家临床阶段的生物技术公司,致力于开发针对物质使用和心理健康障碍的治疗方法。Awakn的近期重点是阿尔科霍尔使用障碍 (AUD),该病影响了美国约2900万成年人以及美国和欧洲关键市场的大约4000万成年人,而目前的标准治疗方法不足以满足需求。我们的目标是为那些迫切需要的成瘾患者提供突破性的治疗方法,而且我们的策略是专注于多渠道推广我们的研发管线。
| LinkedIn | X (formerly Twitter)
| 领英 | X(原推特)
About Graft Polymer (UK) Plc
关于Graft Polymer(UK)Plc
Graft Polymer Plc is an innovative healthcare services company dedicated to helping biopharmaceutical companies specializing in central nervous system disorders enhance the effectiveness of their therapeutics.
Graft Polymer Plc是一家创新的医疗服务公司,致力于帮助专注于中枢神经系统疾病的生物制药公司提高其治疗方法的有效性。
| LinkedIn | X (formerly Twitter)
| 领英 | X(原推特)
Notice Regarding Forward-Looking Information
关于前瞻性信息的通知
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
本新闻稿中含有某些前瞻性信息和前瞻性声明,如适用证券法所定义的那样(以下统称“前瞻性声明”)。“前瞻性声明”反映了关于未来事件或公司未来业绩的目前期望或信念。除历史事实之外,所有陈述均为前瞻性声明。常常但并非总是能够通过使用诸如“计划”、“预计”、“预计”、“预算”、“计划”、“估计”、“继续”、“预测”、“项目”、“预测”、“打算”、“ 预售”或这些单词和短语的变体或这些单词和短语的否定,或者声明某些行动,“事件”或“结果”“可能”,“可能”,“将”,“应该”,“可能”或“将要”被采取,发生或实现,包括涉及公司业务的声明。所有前瞻性声明,包括此处的所有声明均受到本警示声明的约束。
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
尽管公司认为此类声明所表达的期望基于合理的假设,但这些声明并不保证未来业绩,实际结果或发展情况可能与陈述不同。存在某些因素可能导致实际结果与前瞻性信息有所不同。这些因素包括但不限于:宏观经济环境的波动;公司的业务计划和战略;公司能否在高度监管的业务中遵守所有适用政府法规;在某些司法管辖区中目标公司或项目的营运历史有限或没有营运历史,且涉及当前被视为非法活动的活动;法规变化;运营历史有限;依赖管理层;需要获取额外的融资;竞争;证券市场波动性;关于使用致幻药物用于医疗方面的公众意见和感知不一致;对戒瘾市场规模的预期;以及监管或政治变化。读者被警告,上述因素清单并非前瞻性声明影响因素的穷尽清单,请勿过于依赖前瞻性声明。本新闻稿中的前瞻性声明仅反映发表日期或在该等声明中指定的日期或日期。
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at . The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.
投资者需注意,此类陈述并不保证未来业绩,实际结果或发展情况可能与前瞻性信息所述有所不同。有关公司的更多信息,投资者应鼓励查阅该公司在SEDAR的公开申报文件。该公司声明除了法律规定之外,没有任何意图或义务更新或修订任何前瞻性信息。
Investor Enquiries:
投资者查询:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony@awaknlifesciences.com
416-270-9566
Awakn生命科学首席执行官Anthony Tennyson
anthony@awaknlifesciences.com